

# Review of: "Resectable Pancreatic Cancer With Peritoneal Metastases: Is Cytoreduction Combined With Hipec Effective and When?"

Manrica Fabbi<sup>1</sup>

<sup>1</sup> Ospedale di Circolo e Fondazione Macchi Varese

Potential competing interests: No potential competing interests to declare.

The article lacks important details (patients with use of different intraperitoneal drugs are considered - gentamicin in 7 cases, association with cisplatin and Mit-C in another 3) without specifying the reason for the different selection; furthermore, in the follow-up, the localization of recurrence are not correlated with the different therapy administered.

Furthermore, the data should be calculated on the 10 patients (and not on the 13 HIPEC performed)

Moreover:

- The authors have already published a similar article in 2018 (PMID: 29745096), with 6 patients (treated from 2008 to 2016); the current article presents 10 patients (treated from 2011 to 2018) and is like a "copy" of the previous one with the addition of a very few patients.
- They add nothing to the literature (see review published in 2021: 10.1007/s10585-021-10074-2)

In my opinion, the manuscript should be rejected.